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Original articleAltered DNA methylation of glycolytic and
lipogenic genes in liver from obese and type 2
diabetic patientsHenriette Kirchner 1, Indranil Sinha 2, Hui Gao 2, Maxwell A. Ruby 1, Milena Schönke 1, Jessica M. Lindvall 2,
Romain Barrès 3, Anna Krook 4, Erik Näslund 5, Karin Dahlman-Wright 2,6, Juleen R. Zierath 1,3,4,*ABSTRACT
Objective: Epigenetic modiﬁcations contribute to the etiology of type 2 diabetes.
Method: We performed genome-wide methylome and transcriptome analysis in liver from severely obese men with or without type 2 diabetes
and non-obese men to discover aberrant pathways underlying the development of insulin resistance. Results were validated by pyrosequencing.
Result: We identiﬁed hypomethylation of genes involved in hepatic glycolysis and insulin resistance, concomitant with increased mRNA
expression and protein levels. Pyrosequencing revealed the CpG-site within ATF-motifs was hypomethylated in four of these genes in liver of
severely obese non-diabetic and type 2 diabetic patients, suggesting epigenetic regulation of transcription by altered ATF-DNA binding.
Conclusion: Severely obese non-diabetic and type 2 diabetic patients have distinct alterations in the hepatic methylome and transcriptome, with
hypomethylation of several genes controlling glucose metabolism within the ATF-motif regulatory site. Obesity appears to shift the epigenetic
program of the liver towards increased glycolysis and lipogenesis, which may exacerbate the development of insulin resistance.
 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Although the prevalence of type 2 diabetes is approaching epidemic
proportions, the underlying pathophysiology is still not fully under-
stood. The etiology of type 2 diabetes is complex and multifactorial,
as it is inﬂuenced by both genetic predisposition [30] and lifestyle
factors, such as diet and physical activity [14]. The liver is a key
glucoregulatory organ involved in the maintenance of glucose ho-
meostasis and the development of type 2 diabetes [17,31]. In healthy
individuals, insulin promotes hepatic glycogen synthesis and de novo
lipogenesis, while inhibiting gluconeogenesis. However, in obese or
type 2 diabetic patients, insulin fails to suppress hepatic glucose
output, which leads to hyperglycemia via an upregulation of the
gluconeogenic enzymes glucose-6-phosphatase and phosphoenol-
pyruvate carboxykinase [27]. The underlying molecular mechanism
for these shifts in hepatic metabolism is still incompletely resolved
and aberrant regulation of additional metabolic pathways are likely to
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mental factors and genetic susceptibility by modulating transcriptional
regulation without changing the underlying DNA sequence. DNA
methylation is an epigenetic mark that can change in response to
environmental challenges to directly modify gene expression. DNA
methylation can modify gene expression in several ways, for example
by altering histone interactions, inﬂuencing transcription factor bind-
ing, and/or recruitment of methyl-binding proteins [16]. Dynamic DNA
methylation often occurs distal to the transcription start site, with the
position co-localizing with gene regulatory elements, particularly en-
hancers and transcription factor-binding sites [50]. Alterations in DNA
methylation at differentially methylated sites or regions have been
implicated in metabolic diseases such as obesity [24,26,48] and type 2
diabetes [5,26,36,46,47]. Since DNA methylation can lead to stable
alterations in the transcriptional potential, epigenetic mechanisms may
partly explain the rapidly increasing prevalence of type 2 diabetes [23].
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Original articleimprove insulin sensitivity such as exercise [6,36] or bariatric surgery
[4]. Thus, changes in the epigenome may provide an underlying mo-
lecular mechanism for deleterious metabolic health outcomes asso-
ciated with severe obesity or type 2 diabetes. Likewise, coordinated
epigenetic changes may also improve metabolic health after thera-
peutic intervention.
Systematic studies of the DNA methylation landscape and the related
transcriptome of metabolic tissues from obese and/or type 2 diabetic
patients show that DNA methylation is altered in metabolic diseases
[4,24,26,32,33,35,36,40,43,46,47]. For example DNA methylation at
the HIF3A loci in blood cells is correlated with BMI in Caucasian adults
[13]. Moreover, evidence from mouse models indicates that normally
occurring variation in methylation levels contribute to clinically relevant
hepatic traits [37]. Therefore, global epigenome and transcriptome
analysis of human liver in various states of insulin resistance could
offer valuable insight into regulatory mechanisms involved in the
pathogenesis of type 2 diabetes.
To better understand the molecular mechanisms underlying the
development of hepatic insulin resistance and type 2 diabetes, we
performed a genome-wide methylome and transcriptome analysis of
liver from age-matched non-obese metabolically healthy, obese non-
diabetic and obese type 2 diabetic men. We found key genes
involved in hepatic glycolysis and de novo lipogenesis were hypo-
methylated and activated in obese non-diabetic and obese type 2
diabetic patients compared to non-obese control subjects. Our results
indicate the epigenetic landscape in liver is altered in obesity,
concomitant with increased expression of genes involved in hepatic
glycolysis and gluconeogenesis, as well as stearate biosynthesis.
These genomic changes may contribute to the development of insulin
resistance in obesity and type 2 diabetes.
2. RESULTS
2.1. Obese and type 2 diabetic signature of the hepatic methylome
and transcriptome
Liver biopsies were obtained from non-obese men during cholecys-
tectomy and from obese non-diabetic and obese type 2 diabetic men
during Roux-en Y gastric bypass surgery. Anthropometric and clinical
parameters of the study cohort are presented (Table 1). Age was not
different between the cohorts. Body weight, body mass index (BMI) and
waist circumference did not differ between the obese non-diabetic and
obese type 2 diabetic patients, but was increased compared to the
non-obese participants. While plasma triglycerides, high density lipo-
protein cholesterol (HDL) and low density lipoprotein cholesterol (LDL)
levels were unchanged between the cohorts, fasting serum glucose,
glycated hemoglobin (HbA1c) and homeostatic model assessment e
insulin resistance (HOMA-IR) levels were increased in the obese type 2
diabetic patients compared to the non-obese controls and obese non-
diabetic patients.
To identify novel regulatory mechanisms involved in the pathogenesis
of obesity and type 2 diabetes, we determined the hepatic methylome
of 7 non-obese metabolically healthy, 7 obese non-diabetic and 8
obese type 2 diabetic Caucasian men of similar age using the Illumina
Inﬁnium 450K Bead Chip. We also assessed the hepatic transcriptome
using Affymetrix gene arrays of liver biopsies obtained from 18 in-
dividuals (6 from each group). Samples from 17 of the subjects were
subjected to both the transcriptome and methylome analysis. Meth-
ylome data were ﬁltered for detection and analyzed according to the
Beta Mixture Quantile dilation (BMIQ) method [29]. Employing a
multigroup comparison, 5834 CpG loci were identiﬁed to be differ-
entially methylated among the three groups (FDR< 0.25). Hierarchical172 MOLECULAR METABOLISM 5 (2016) 171e183  2016 The Authors. Published by Elsevier GmbH. Thclustering and principal component analysis (PCA), based on the
differentially methylated sites, revealed a clear separation of the three
phenotypic groups, with the obese non-diabetic group being well-
separated from the obese type 2 diabetic and non-obese group
(Figure 1A,B). In total, 5682 CpG sites mapping to 3058 individual
genes were differentially methylated in obese non-diabetic individuals
versus non-obese controls (p < 0.05; Tables S1 and S2). Moreover,
2255 CpG sites mapping to 1388 individual genes were differentially
methylated between obese type 2 diabetic individuals compared to
non-obese controls (p < 0.05; Table Tables S1 and S2). In particular,
the vast majority of CpG sites displayed decreased DNA methylation in
obese non-diabetic and obese type 2 diabetic individuals, compared to
non-obese controls (97 and 92%, respectively; Figure 1C). The dis-
tribution of the absolute differences in DNA-methylation between
obese non-diabetic versus non-obese controls and obese type 2 dia-
betic individuals versus non-obese controls is shown in Figure 1D.
To investigate whether obesity and/or type 2 diabetes is associated
with alterations in global DNA methylation, and/or alterations in the
methylation proﬁle at speciﬁc genomic positions, the distribution of
altered CpG sites was mapped according to deﬁned CpG categories
and in relation to the nearest gene. Although distinct changes in DNA
methylation were associated with obesity and type 2 diabetes
(Figure 1), global DNA methylation with regard to CpG categories was
similar between the three cohorts (Figure S1A). Additionally, genomic
distribution of the differentially methylated sites with regard to the
nearest gene was similar between the cohorts (Figure S1B). In general,
differential DNA-methylation was observed at speciﬁc loci, rather than
spread over larger chromosomal areas (data not shown), as is often
observed in various cancers [45].
PCA analysis based on overall gene expression, separated the three
groups into distinct clusters (Figure 2A). Analysis of differences in gene
expression proﬁles between the groups revealed that 448 transcripts
were differentially expressed in obese non-diabetic individuals versus
non-obese controls (FDR  0.25; Table S3). Moreover, 1285 tran-
scripts were differentially expressed in obese type 2 diabetic in-
dividuals versus non-obese controls (FDR  0.25; Table S3). Only 11
transcripts were identiﬁed as differentially expressed in obese non-
diabetic individuals versus obese type 2 diabetic individuals.
Canonical pathway analysis was employed to identify pathways in the
liver that are altered in obesity and type 2 diabetes. Interestingly,
there was substantial overlap between pathways altered in obese
non-diabetic individuals compared to non-obese controls and path-
ways altered in obese type 2 diabetic individuals compared to non-
obese controls (Figure 2B). For example, genes involved in stearate
biosynthesis, AMPK signaling and PI3K/AKT signaling were affected
in both obese non-diabetic, as well as obese type 2 diabetic in-
dividuals compared to non-obese controls (Figure 2C). Genes
involved in gluconeogenesis and glycolysis were speciﬁcally altered
in liver from obese non-diabetic individuals compared to non-obese
controls (Figure 2D; upper panel). Moreover, transcripts involved in
PXR/RXR activation were speciﬁcally altered in obese type 2 diabetic
individuals compared to non-obese individuals (Figure 2D; lower
panel).
2.2. Correlation of the obese and type 2 diabetic hepatic
methylome and transcriptome
Figure 3A,B displays CpG sites with altered DNA-methylation and
where the expression of the associated gene is changed for obese
non-diabetic individuals versus non-obese controls and obese type 2
diabetic individuals versus non-obese controls, respectively. Overall,
we identify 36 and 61 genes with signiﬁcantly altered expressionis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1 e Clinical Parameters.
Non-Obese Controls Obese Non-Diabetic Obese Type 2 Diabetic
Transcriptomic
analysis
Methylomic
analysis
Complete
cohort
Transcriptomic
analysis
Methylomic
analysis
Complete
cohort
Transcriptomic
analysis
Methylomic
analysis
Complete
cohort
N (male) 6 7 11 6 7 13 6 8 10
Age [years] 40.5 (36.7e49.0)
 4.1
42.7 (36.2e59.1)
 7.8
41 (34.0e59.1)
 6.8
41.6 (32.5e50.5)
 6.7
45.8 (36.4e59.8)
 7.6
44 (32.5e59.8)
 8.3
40.9 (21.4e62.1)
 13.0
41.2 (21.4e62.1)
 11.3
43 (21.4e62.1)  11.4
Body weight [kg] 83.3 (71.6e89.1)
 7.2
80.8 (71.6e89.1)
 6.8
82.3 (68.0e89.1)
 7.3
120.0 (114.0e140.0)
 9.26a
123.6 (114.0e144.0)
 12.0a
136.9 (114.0e201.)
 26.5a
136.3 (104.0e154.0)
 16.3a
132.9 (104.0e154.0)
 15.4a
132.8 (104.0e154.0)
 13.8a
BMI [kg/m2] 26.1 (22.6e28.4)
 2.0
25.4 (22.6e27.8)
 1.7
25.7 (20.0e28.4)
 2.4
38.9 (35.6e41.6)
 2.1a
38.6 (35.6e41.6)
 2.0
42.1 (35.6e56.5)
 6.3a
40.9 (36.0e45.8)
3.3a
40.3 (36.0e45.8)
3.1a
40.6 (36.0e45.8) 3.1a
Waist
circumference
[cm]
91.5 (80.0e102.0)
 7.4
90.6 (80.0e100.0)
 6.6
92.0 (80.0e102.0)
 7.2
126.3 (114.0e140.0)
 8.7a
125.7 (114.0e140.0)
 8.7a
126.9 (114.0e140.0)
 8.7a
137.5 (121.0e143.0)
 7.6a
133.5 (118.0e143.0)
 9.7a
133.5 (118.0e143.0)
 9.7a
Fasting
glucose [mmol/l]
5.5 (4.9e5.9)  0.4 5.4 (4.8e5.9)  0.4 5.6 (4.8e6.3)  0.4 5.6 (5.3e5.9) 0.2 5.5 (5.2e5.9) 0.2 5.6 (5.1e6.1) 0.3 8.4 (6.6e13.4)
 2.3a,b
8.2 (6.6e13.4)
 2.1a,b
8.4 (6.6e13.4)  2.0a,b
HbA1c [%] 4.6 (4.2e5.0)  0.2 4.6 (4.2e5.0)  0.2 4.6 (4.2e5.0)  0.2 4.7 (4.3e5.0)  0.3 4.7 (4.2e5.0)  0.3 4.7 (4.2e5.0)  0.3 6.0 (5.2e7.9)  0.8a,b 6.2 (5.2e7.9)  1.0a 6.1 (5.2e7.9)  0.9a,b
Fasting insulin
[pmol/l]
74.8 (40.0e189.0)
 51.9
67.9 (27.0e189.0)
 50.9
73.0 (27.0e189.0)
 41.7
136.0 (72.5e183.9)
 42.7a
139.0 (72.5e199.7)
 44.9
127.7 (72.5e199.7)
 42.9a
205.1 (151.6e299.6)
 49.1a
196.7 (146.5e299.6)
 49.9a
180.6 (115.0e299.6)
 53.6a
HOMA-IR 2.7 (1.5e6.9)  1.9 2.4 (0.9e6.9)  1.9 2.2 (0.9e6.9)  1.5 4.8 (2.6e6.4)  1.5 4.8 (2.6e6.6)  1.4 5.0 (2.6e6.8)  1.5a 10.6 (8.0e13.0)
 2.1a,b
10.2 (7.7e13.0)
 2.2a,b
9.6 (7.5e13.0)  2.2a,b
LDL [mmol/l] 3.2 (1.8e3.9)  0.7 3.4 (1.8e4.7)  0.8 3.3 (1.8e4.7)  0.8 3.6 (2.3e4.4)  0.7 3.6 (2.3e4.4)  0.7 3.5 (2.3e4.4)  0.6 3.2 (1.7e4.9)  1.1 3.0 (1.3e4.9)  1.7 3.0 (1.3e4.9)  1.2
HDL [mmol/l] 1.2 (0.9e1.5)  0.2 1.1 (0.7e1.5)  0.3 1.1 (0.7e1.5)  0.3 1.1 (0.4e1.4)  0.3 1.2 (0.4e2.0)  0.4 1.2 (0.4e2.0)  0.4 0.8 (0.6e1.0)  0.2 1.2 (0.6e3.9)  1.0 1.2 (0.6e3.9)  1.0
Plasma
triglycerides
[mmol/l]
1.2 (0.6e2.2)  0.5 1.2 (0.6e2.2)  0.5 1.2 (0.6e2.2)  0.5 1.7 (1.2e2.6)  0.5 1.7 (0.9e2.6)  0.5 1.6 (0.9e2.6)  0.5 2.1 (1.2e3.3)  0.7 1.9 (1.2e3.3)  0.7 1.9 (1.2e3.3)  0.7
Liver
triglycerides
[mM/mg]
7.5 (2.0e16.9)
 5.6
7.9 (2.0e16.9)  6.1 12.6 (2.0e43.1)
 14.4
63.3 (12.4e95.6)
 30.9a
47.0 (12.4e95.6)
 36.4c
37.7 (6.0e95.6)
 31.6
40.3 (6.1e88.3)
 30.7
41.0 (6.1e88.3)
 31.0
33.4 (6.1e88.3)  28.5
Data are mean (minimumemaximum)  SD from the cohort used for transcriptomic and methylomic analysis and the entire cohort; Differences between groups were analyzed by one way ANOVA and Tukey’s multiple comparisons test.
a P < 0.05 versus non-obese controls in same cohort.
b P < 0.05 versus obese non-diabetic patients in same cohort.
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Figure 1: The human methylome in obese non-diabetic, obese type 2 diabetic and non-obese individuals. (A) Hierarchical clustering for 5834 differentially methylated sites
derived from multi-group comparison (FDR < 0.25). (B) Principal component analysis (PCA) of 5834 differentially methylated sites for the major two principal components (PC). The
95% conﬁdence ellipses are shown for each group. (C) Pie chart indicating the number of sites that exhibit increased and decreased DNA methylation in liver from obese non-
diabetic and obese type 2 diabetic individuals compared to non-obese controls. (D) Distribution of the absolute difference in DNA-methylation in liver from obese non-diabetic and
obese type 2 diabetic individuals compared to non-obese controls.
Original articlewhere one, or several, CpG sites display altered DNA-methylation.
Among the genes with altered expression and DNA-methylation in
obese type 2 diabetic individuals compared to non-obese controls are
several genes belonging to the nerve growth factor signaling and Wnt
signaling pathways. Speciﬁcally, six genes that are involved in the
nerve growth factor signaling pathway display increased expression
and decreased DNA-methylation in obese type 2 diabetic individuals
compared to non-obese controls; PRKCE (protein kinase C, epsilon),
ABR (active BCR-related), PDGFA (platelet-derived growth factor
alpha polypeptide), ARHGEF16 Rho guanine nucleotide exchange
factor (GEF) 16, ADCY6 (adenylate cyclase 6) and RPS6KA1174 MOLECULAR METABOLISM 5 (2016) 171e183  2016 The Authors. Published by Elsevier GmbH. Th(ribosomal protein S6 kinase, 90 kDa, polypeptide 1). Activation of
PRKCE has been implicated as a key switch leading to decreased
insulin signaling in the pathogenesis of hepatic insulin resistance and
type 2 diabetes, as well as NAFLD [9]. Three additional genes
involved in the Wnt signaling pathway also showed increased
expression and decreased DNA-methylation in obese type 2 diabetic
individuals compared to non-obese controls; CTBP1 (C-terminal
binding protein 1), CCND1 (Cyclin D1) and WNT11 (wingless-type
MMTV integration site family, member 11). This analysis identiﬁes
several genes that are differently regulated in liver between obese
type 2 diabetic individuals and obese non-diabetic individuals,is is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
Figure 2: Canonical pathway analysis of changes in the hepatic transcriptome for obese non-diabetic and obese type 2 diabetic individuals compared to non-obese
individuals. (A) PCA on the overall gene expression proﬁle based on all annotated transcripts for two major principal components (PC). The 95% conﬁdence ellipses are shown for
each group. (B). Venn diagram of pathways changed in obese non-diabetic individuals compared to non-obese controls and obese type 2 diabetic individuals compared to non-
obese controls. (C). The top 10 pathways changed in both obese type 2 diabetic individuals compared to non-obese controls and obese non-diabetic individuals compared to non-
obese controls. (D) The top 10 pathways speciﬁcally changed in obese non-diabetic individuals compared to non-obese controls or obese type 2 diabetic individuals compared to
non-obese controls, respectively. Log p-values are shown at the bottom of the C and D panels. The red lines in C and D indicate threshold signiﬁcance for enrichment,
P-value 0.05.respectively, and non-obese controls and provides a useful resource
for future studies to interrogate gene regulatory responses in human
liver, as well as the impact of metabolic disease.
We further identiﬁed differentially methylated CpG-sites that show an
inverse change in mRNA expression of the associated gene (Table S2,
column overlay). A summary of these sites is provided as Table S4. A
detailed comparison between the liver methylome and the tran-
scriptome revealed 23 genes, including 26 differentially methylated
CpG sites, where decreased DNA-methylation is associated with
increased mRNA expression in obese non-diabetic individuals
compared to non-obese controls (Table S2 column negative correla-
tion). In obese type 2 diabetic individuals compared to non-obese
controls we observed a correlation between increased mRNA
expression and decreased DNA-methylation for 33 genes, including 40
differentially methylated CpG sites (Table S2 column negativeMOLECULAR METABOLISM 5 (2016) 171e183  2016 The Authors. Published by Elsevier GmbH. This is an
www.molecularmetabolism.comcorrelation). As the vast majority of CpG sites displayed decreased DNA
methylation in the obese non-diabetic and obese type 2 diabetic in-
dividuals, the number of genes where increased DNA-methylation was
associated with decreased mRNA expression is very low and only 2
genes, including 2 differentially methylated CpG sites, were observed,
both in obese type 2 diabetic individuals compared to non-obese
controls (Table S2 column negative correlation).
We also investigated the correlation between changes in DNA-
methylation and gene expression for the individual samples using
Pearson correlation analysis. Supplementary Figure S2A shows the
number of DNA-methylation sites with a negative or positive correlation
to the expression of the associated gene that are equal or larger than a
correlation coefﬁcient r value of 0.6. Supplementary Figure S2B shows
examples of DNA-methylation sites that are positively and negatively
correlated to the expression of the associated gene. Finally,open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 175
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Figure 3: Top candidate genes and transcription factors altered in obesity and type 2 diabetes. Fold change gene expression (y-axis; log2 value) was plotted against the
change in DNA methylation (x-axis; M-value) for non-diabetic obese individuals versus non-obese controls (A) and obese type 2 diabetic individuals versus non-obese controls (B).
Top 10 transcription factors that are predicted by ISMARA to be activated (positive Z-values) or inactived (negative Z-values) in liver of (C) non-obese controls, (D) obese non-
diabetic patients and (E) obese type 2 diabetic patients. See also Tables S5eS7.
Original articleSupplementary Figure S2C shows the distribution of altered CpG sites
with regard to deﬁned CpG categories and in relation to the nearest
gene.
2.3. Hypomethylation of ATF-motifs in liver from obese type 2
diabetic patients
To identify motifs and key transcription factors that drive the observed
changes in hepatic gene expression between the obese non-diabetic,
obese type 2-diabetic and non-obese cohorts, we performed an In-
tegrated System for Motif Activity Response Analysis (ISMARA) [3].
This unbiased approach identiﬁed that distinct motifs and transcription
factors are likely to be active in each of the cohorts, and this may
explain the observed alterations in gene expression. While genes
under the control of the transcription factor activating transcription
factor 4 (ATF4) were predicted by the ISMARA analysis to be inactive in
liver from the non-obese controls (Figure 3C), genes regulated by
ATF6, a transcription factor belonging to the same family as ATF4,
were predicted to be activated in obese type 2 diabetic patients
(Figure 3E). Conversely, the activity of FOX[D1,D2] was predicted to be
high in non-obese controls, and low in obese type 2 diabetic patients
(Figure 3D,E). Furthermore, the ISMARA analysis suggests that
PRRX1,2 target genes are inactive in obese type 2 diabetic patients,
whereas target gene expression suggests high PRRX1,2 activity in
obese non-diabetic patients (Figure 3D,E). Furthermore, we mapped
DNA methylation and mRNA of the target genes from the top three
active and top three inactive transcription factors in non-obese con-
trols (Table S5), obese non-diabetic patients (Table S6), and obese
type 2 diabetic patients (Table S7) using our genome-wide data. This
approach identiﬁed the most likely active and inactive transcription176 MOLECULAR METABOLISM 5 (2016) 171e183  2016 The Authors. Published by Elsevier GmbH. Thfactors in liver from obese non-diabetic and obese type 2 diabetic
patients and serves as a resource for further studies to interrogate DNA
methylation and gene expression of target genes.
The ISMARA analysis implicates genes that are differently expressed
between the non-obese controls and obese type 2 diabetic patients are
likely under the transcriptional control of members of the ATF-family.
Thus, we investigated methylation and activity of the ATF-family bind-
ing motif in human liver. The ATF-family shares a common recognition
motif that contains a CpG-site (Figure 4A), which may play a role in the
regulation of gene transcription by DNA methylation [10]. To test
whether methylation of the CpG-site within this common ATF-motif is
altered in obesity and/or type 2 diabetes, the hepatic methylation status
of this ATF-CpG-site (TGCGTCA; Figure 4B) in candidate genes was
quantiﬁed by pyrosequencing. Acetyl-CoA carboxylase alpha (ACACA) is
a predicted target gene of ATF6 that was activated in liver from obese
type 2 diabetic patients. ACACA transcription was also identiﬁed to be
upregulated by the canonical pathway analysis (Figure 3). Therefore we
searched for an ATF-family-motif within ACACA and other genes
identiﬁed by the canonical pathway analysis belonging to “Type 2
diabetes signaling” and “Glycolysis/Gluconeogenesis” pathways.
Several genes involved in hepatic glycolysis (GCK glucokinase and PFKL
phosphofructokinase, liver), de novo lipogenesis (ACLY ATP citrate
lyase, ACACA and FASN fatty acid synthase) and insulin signaling
(PRKCE protein kinase Cε) contain an ATF-motif in their gene body.
Thus, we selected these genes for in-depth analysis. Interestingly, the
genome-wide DNAmethylation assay identiﬁed at least one signiﬁcantly
hypomethylated CpG site in association with these target genes in obese
non-diabetic and obese type 2 diabetic patients, compared to non-
obese controls (Table S8).is is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 4: Hypomethylation of the common ATF-motif in liver. (A) Position weight matrix of the consensus sequence of the ATF binding motif (from Motifmap, www.motifmap.
ics.uci.edu). (B) Consensus sequence of the ATF motif present in the gene body of GCK, PFKL, ACACA, ACLY, FASN and PRKCE was analyzed for CpG methylation by pyrose-
quencing. Methylation of the CpG-site covering an ATF binding motif and the next associated CpG site was measured in the (C) GCK, (D) PFKL, (E) ACACA, (F) ACLY (G) FASN and (H)
PRKCE, respectively by pyrosequencing of bisulﬁte treated DNA in liver from non-obese controls (n ¼ 11), obese non-diabetic patients (ND; n ¼ 13) and obese type 2 diabetic
patients (T2D; n ¼ 11). Numbers on the x-axis represent the base count of the analyzed cytosines starting from the transcriptional start site of each gene. *p < 0.05 vs. non-obese
controls; **p < 0.01 vs. non-obese controls; ***p < 0.001 vs. non-obese controls using one way ANOVA with Tukey’s multiple comparisons test. (I) Luciferase assay for the
speciﬁc region covering the common ATF motif in PFKL, ACACA, FASN and PRKCE that were pyrosequenced in BeH. **p < 0.01 vs. non-methylated; ***p < 0.001 vs. non-
methylated using unpaired two-tailed Students t-test. See also Tables S8eS9.Methylation of the common ATF-motif in GCK was unchanged
(Figure 4C) in liver from obese non-diabetic and obese type 2 diabetic
patients. Methylation of the ATF-motif in the gene body of PFKL
(Figure 4D) and ACACA (Figure 4E) was reduced in obese non-diabetic
and obese type 2 diabetic patients compared to non-obese controls.
Conversely, ACLY methylation was unaltered (Figure 4F). ATF
methylation in the FASN gene body tended to decrease, but this did notMOLECULAR METABOLISM 5 (2016) 171e183  2016 The Authors. Published by Elsevier GmbH. This is an
www.molecularmetabolism.comreach signiﬁcance. However the proximal CpG-site to the ATF-motif in
FASN (Figure 4G) and the ATF-motif in PRKCE (Figure 4H) was hypo-
methylated in obese non-diabetic and obese type 2 diabetic patients
compared to non-obese controls.
mRNA expression and protein abundance of these genes was
assessed (Figure 5). RT-qPCR showed that GCK expression was un-
changed between the cohorts, consistent with unchanged DNAopen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 177
Figure 5: mRNA expression and protein abundance of glycolytic and lipogenic genes in liver. A) Gene expression of glycolytic and lipogenic genes containing the common
ATF-motif in liver of non-obese controls (n ¼ 9), obese non-diabetic patients (ND-obese, n ¼ 12) and obese type 2 diabetic patients (T2D-obese n ¼ 8) was measured by TaqMan
qPCR. Data are normalized to the geometric mean of RPL32 and TBP gene expression and calculated as fold-change relative to the non-obese controls. (B) Western Blot analysis of
liver abundance of FASN, ACC and GAPDH. A representative blot each group is shown and bar graphs show quantiﬁed data for liver (C) ACCa, (D) FASN and (E) PRCKε from non-
obese controls (n ¼ 10), obese non-diabetic patients (n ¼ 7) and obese type 2 diabetic patients (n ¼ 5). Data are mean  SEM analyzed using one-way ANOVA with Tukey’s
multiple comparisons test. *p < 0.05 vs. non-obese; **p < 0.01 vs. non-obese controls; ***p < 0.0001 vs. non-obese controls; ****p < 0.00001 vs. non-obese controls;
###p < 0.0001 vs. ND-obese. See also Figs. S3 and S5.
Original articlemethylation at the ATF-motif, while PFKL mRNA expression was
increased in obese non-diabetic patients versus non-obese controls
(Figure 5A). However, total liver glycogen content was unaltered be-
tween the cohorts (Fig. S3). mRNA expression of the lipogenic genes
ACLY, ACACA and FASN was increased in obese non-diabetic and
obese type 2-diabetic patients (Figure 5A). Consistent with the
increased mRNA expression, protein abundance of ACCa/b (Figure 5B
and Figure 5C) and FASN (Figure 5B and Figure 5D) was increased in
obese non-diabetic and obese type 2 diabetic patients. PRKCE mRNA
expression (Figure 5A) and protein content (Figure 5B and Figure 5E)
was increased only in obese non-diabetic patients. Notably, the pattern
of DNA methylation at the ATF-family-motif in non-diabetic and type 2
diabetic obese patients inversely mirrored mRNA expression, except
for ACLY. Thus, our results suggest DNA methylation of the ATF-
binding motif regulates the expression of these genes.
We performed luciferase reporter assays to determine whether DNA
methylation of the ATF-binding motif within PFKL, ACACA, FASN and
PRCKE regulate mRNA expression of each respective gene. Gene se-
quences of PFKL, ACACA, FASN and PRCKE that were analyzed by
pyrosequencing above (Figure 4) were cloned into a CpG-free vector
containing a promoter and a luciferase gene. Methylation of the ATF-
motif decreased luciferase activity for all four candidate genes
(Figure 4I). ATF6 silencing altered expression of PFKL, FASN, ACLY,
ACACA and PRKCE in Huh7 cells studied under basal or tunicamycin-
stimulated condition (Fig. S4).
Methylation of the ATF-motif within PFKL and ACACA correlated with
body weight, BMI and waist circumference (Table S9), whereas that of178 MOLECULAR METABOLISM 5 (2016) 171e183  2016 The Authors. Published by Elsevier GmbH. ThFASN, PRKCE, PFKL and ACACA correlated with blood glucose, HbA1c,
insulin and HOMA-IR. Methylation of the ATF-motif within ACLY, which
was not altered between cohorts, did not correlate with the clinical
characteristics of the participants (Table S9).
To further interrogate our results, we compared our results in human
liver against the ENCODE ChIP-SEQ data available for MBD4 (HepG2
cells). When all differentially methylated sites identiﬁed in human liver
in this study were overlaid with the MBD4 ChIP SEQ data, we identiﬁed
35 DNA methylation sites with 31 unique genes in obese non-diabetic
patients versus non-obese controls, 19 DNA methylation sites with 15
unique genes in obese type 2-diabetic versus non-obese patients, and
12 DNA methylation sites with 11 unique genes were found in obese
non-diabetic versus obese type 2 diabetic patients (Table S10).
Nevertheless, this overlay analysis did not reveal binding of MBD4 to
the ATF-motifs studied in Figure 4.
3. DISCUSSION
We provide a genome-wide cartography of the liver methylome and
transcriptome in age-matched healthy, obese non-diabetic, and obese
type 2 diabetic Caucasian men. Unlike other studies [1,15,19,33,49],
liver biopsies were also collected from non-obese otherwise healthy
men undergoing elective gallbladder surgery. These individuals did not
suffer from non-alcoholic fatty liver disease (NAFLD) or other malign
conditions such as cancer, which is known to alter DNA methylation
[45]. The genomic maps presented here for healthy versus metabolic
disease states constitute a resource that will facilitate translationalis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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approaches to identify and validate rational intervention strategies to
improve hepatic insulin sensitivity in obesity or type 2 diabetes.
Consistent with an earlier study [35], we report that the majority of
DNA-methylation sites modiﬁed in liver from obese type 2 diabetic
individuals show hypomethylation. Moreover, the expression of PRKCE
may undergo regulation by DNA methylation. This ﬁnding is of
particular interest given that Protein Kinase C (PKC) epsilon activation
is implicated in hepatic insulin resistance [41,42].
Using unbiased ISMARA and gene ontology approaches, we predicted
differential activation of the ATF-family and identiﬁed expression
changes of ATF-target genes in liver from obese non-diabetic and
obese type 2 diabetic patients. Using a pyrosequencing approach, we
validated that the ATF motif present in metabolic genes is hypo-
methylated in liver from obese non-diabetic and obese type 2 diabetic
patients compared to non-obese controls. Overexpression of ATF6 in
zebra ﬁsh leads to alcohol-induced hepatic steatosis via activation of
fatty acid synthase [20], highlighting the metabolic role of this tran-
scription factor. Somewhat surprisingly, ATF6 silencing in cell cultures
increased expression of the investigated genes. While our results
support a role for ATF in the regulation of these genes, the unexpected
direction of this expression change could be related to the nature of the
in vitro studies, in particular given that in vitro modulation of ATF
expression does not always reﬂect the direction of gene expression
change observed in vivo [20]. Nevertheless, we report that DNA
methylation of ATF binding elements decreases expression of glyco-
lytic and lipogenic target genes in vitro (Figure 4I). Thus, the methyl-
ation state of ATF binding sites may regulate glycolytic and lipogenic
genes, providing a possible mechanism for an epigenomic regulation
of glucose and lipid metabolism in liver from obese non-diabetic and
obese type 2 diabetic patients. This hypothesis is supported by the
ﬁnding that the CpG-site within the ATF3-motif is a critical recognition
site, which is unmethylated in HCT116 colorectal cancer cells when
ATF3 is bound [10].
The gluconeogenic genes glucose-6-phosphatase and phosphoenol-
pyruvate carboxykinase are upregulated in liver of obese humans and
rodents [17,27]. Here we report that DNA methylation of these two
genes was unaltered (data not shown), while glucose-6-phosphatase
mRNA was down-regulated in obese type 2 diabetic individuals
compared to non-obese controls (Tabel S2). Moreover, we report that
transcription of the glycolytic gene PFKL was increased in conjunction
with DNA hypomethylation, implicating increased glycolysis with
obesity. In addition, we found genes involved in stearate synthesis, a
pathway downstream of glycolysis, were hypomethylated and the
transcripts were simultaneously increased in liver from obese patients.
Increased lipogenesis may be an adaptive response in obesity to cope
with the increased hepatic glucose load since excess glucose not
utilized by the liver for energy production is converted to lipids.
However, hepatic lipid production also impairs insulin signaling, thus
increased lipogenesis is likely to promote insulin resistance [25].
Moreover, insulin directly stimulates hepatic de novo lipogenesis
[18,38] even in states of hepatic insulin resistance [11]. We also found
altered DNA methylation of lipid and cholesterol metabolism pathways
in liver from obese non-diabetic and obese type 2 diabetic patients. In
particular, lipogenic genes ACLY, ACACA and FASN were hypo-
methylated in obese non-diabetic and obese type 2 diabetic patients.
Thus, an upregulation of glycolysis facilitated by hypomethylation of
the ATF-binding motif may fuel de novo lipogenesis. Taken together
the ATF-associated hypomethylation of these lipogenic genes may
disrupt hepatic insulin signaling and contribute to development of in-
sulin resistance in obesity.MOLECULAR METABOLISM 5 (2016) 171e183  2016 The Authors. Published by Elsevier GmbH. This is an
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[1,21,25]. Here we provide evidence for PRKCε activation in liver from
obese non-diabetic and obese type 2 diabetic patients, which may
contribute to the development of hepatic insulin resistance and type 2
diabetes. We propose that site speciﬁc DNA hypomethylation promotes
pathological activation of glycolysis and subsequently de novo lipo-
genesis via increased stearate synthesis, which may be facilitated by
ATF transcription factors activation and increased gene transcription
(Figure 6). Transcription factors belonging to the ATF-family are stress-
inducible and responsive to metabolic dysregulation. For example,
pancreatic ATF3 activation is involved in glucose homeostasis after
partial pancreatectomy or streptozotocin treatment [2]. Furthermore,
peroxisome proliferator-activator receptor (PPAR) activators can induce
ATF3 activation providing additional support for a role for ATF3 in
regulation of metabolism [34].
Distinct hepatic epigenetic signatures characterize patients with
NAFLD [1,33]. In patients undergoing liver biopsy for suspected
NAFLD, or intraoperatively for assessment of liver histology, obesity
accelerates epigenetic aging of liver by 3.3 years for each 10 BMI units
[20]. Our results in obese non-diabetic and obese type 2 diabetic
patients provide additional insight into mechanisms by which epige-
netic modiﬁcations reprogram the liver towards insulin resistance.
Gene-speciﬁc alterations in DNA methylation can be induced in
cultured cells exposed to high levels of lipids or inﬂammatory cytokines
[5], Hence, DNA methylation may be altered in response to obesity-
induced metabolic changes. Although we are unable to determine
whether alterations in DNA methylation are a cause or consequence of
obesity or type 2 diabetes, similarities between DNA methylation
proﬁles in obese non-diabetic and obese type 2 diabetic patients were
observed. Our ﬁnding of normal HbA1c and lower HOMA-IR in the obese
non-diabetic versus obese type 2 diabetic patients support the notion
that obesity alters DNA methylation before or at an early stage in the
development of type 2 diabetes. Moreover, as the data by necessity are
from a cross-sectional analysis from human subjects undergoing
surgery, we are unable to establish a direct causation between altered
methylation and gene expression, and it remains possible that the
relationship is bidirectional. Notably, obesity-alterations in DNA
methylation in whole blood, skeletal muscle, adipose tissue and liver
can be partly reversed by gastric bypass [1,4,22,32], indicating DNA
methylation is a dynamic process.
Overall, the difference in hepatic DNA methylation between both obese
patient groups and the non-obese control subjects were signiﬁcant,
but the changes were modest, consistent with previous ﬁndings that
environmental inﬂuences, including metabolic diseases, alter DNA
methylation in a site-speciﬁc and subtle manner [1,36,47,50].
Conversely, in cancer, DNA methylation of larger genomic areas is
robustly modiﬁed, and differences between cohorts more evident [45].
The modest sample size in our study may account for the fact that only
subtle changes in gene expression and DNA methylation were noted
between groups. Nevertheless, the glycolytic and lipogenic target
genes selected for more thorough analysis were also validated by
qPCR, pyrosequencing, and protein abundance, providing secondary
validation that the changes in expression and DNA methylation impact
speciﬁc gene function. We also provide evidence of methylation-
dependent function of the ATF-motif and ATF6 expression, high-
lighting a possible mechanism for the regulation of speciﬁc target
genes. Thus, metabolic diseases induce modest, but clinically relevant
changes in the epigenome, consistent with the epigenetic signature for
enhanced hepatic de novo lipogenesis observed in independent cohort
of obese patients [1].open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 179
Figure 6: Increased hepatic glycolysis and de novo lipogenesis is associated with DNA hypomethylation. Hypomethylation of the ATF-binding motif of the obese liver
“unlocks” the glycolytic and lipogenic pathways. An overabundance of pyruvate from glycolysis is not used for ATP production in the TCA cycle, but is instead converted to fatty
acids. These in turn activates protein kinase Cε, which is also locked into an “on position” by hypomethylation. Thus, the obese liver is programmed by a feed forward loop to
become insulin resistant, possibly contributing to the development of type 2 diabetes and fatty liver. Orange arrows represent activation of glycolysis and lipogenesis that were
studied. Turquoise arrows represent hypothesis.
Original articleIn conclusion, mRNA expression of targets along the glycolytic pathway
are increased in liver of obese people, concomitant with DNA hypo-
methylation of their respective genes at an important ATF-motif reg-
ulatory site. Constitutive activation of theses pathways is associated
with PRKCE activation and hypomethylation, which may lead to the
development of hepatic insulin resistance and hepatic steatosis. This
hepatic epigenetic signature contributes to the understanding of the
underlying etiology of metabolic dysfunction in obesity and type 2
diabetes and identiﬁes new targets for the development of therapeutic
strategies to combat insulin resistance.
4. EXPERIMENTAL PROCEDURES
4.1. Patients
This study was conducted according to the principles described in the
Declaration of Helsinki. The regional ethics committee at Karolinska
Insitutet approved the study. All participants provided informed written
consent. Liver biopsies (100e200 mg) were collected from 11 non-
obese men during cholecystectomy and from 13 obese non-diabetic
and 11 obese type 2 diabetic men during Roux-en Y gastric bypass
surgery, providing a total cohort of 35 subjects. Biopsies were ﬂash-
frozen and stored in liquid nitrogen until analysis. Clinical parame-
ters of the study cohort are presented (Table 1).
4.2. Genome-wide DNA methylation analysis
Genomic DNA was extracted with the DNeasy kit (Qiagen, Hilden,
Germany) and assays were performed according to the manufacturer’s
protocol. The hepatic methylome was analyzed using the Illumina
Inﬁnium human methylation 450K beadchip arrays (Illumina, San
Diego, CA, USA) from 22 randomly chosen subjects out of the entire
cohort (7 non-obese, 7 obese non-diabetic and 8 obese type 2 dia-
betic). Each array includes 485,577 probes, targeting 21,231 (99%)180 MOLECULAR METABOLISM 5 (2016) 171e183  2016 The Authors. Published by Elsevier GmbH. ThRefSeq genes and 125401 (96%) CpG island regions [7,8]. The Illu-
mina 450K array contains two different assays, Inﬁnium I and Inﬁnium
II. The methylation values acquired from these two assays show
different distributions [12]. To correct for this bias, several data
normalization methods were proposed [12,28,44]. The BMIQ method
was recently shown to outperform other methods [29]. Thus, we
applied the BMIQ method in the present study. All samples were
ﬁltered for detection p-value <0.001, adjusted for color bias and
normalized using the Quantile normalization method and the lumi
package, followed by the BMIQ normalization method in R Bio-
conductor (http://www.bioconductor.org). Cross reactive probes and
probes including SNPs with minor allele frequency (MAF) > 5% ac-
cording to Illumina were removed leaving 427,550 methylation sites
for further analysis. The Beta-value, which is the ratio of the methyl-
ated probe intensity versus the unmethylated probe intensity and the
M-value, which is the log2 ratio of the intensity of the methylated probe
versus the unmethylated probe values, were generated. The M value
was used for further analysis and signiﬁcant differences in methylation
were identiﬁed after multi-group comparison with FDR <0.25.
Differentially methylated sites between 2 groups were identiﬁed by t-
test (p < 0.05). Qlucore Omics Explorer (Qlucore AB, Lund, Sweden)
was used to calculate multi-group comparison and to generate heat
maps.
4.3. Genome-wide mRNA expression and RT-qPCR analysis
Total RNA was extracted using the miRNeasy kit (Qiagen, Hilden,
Germany) and RNA integrity was validated with the Bioanalyzer
(Aglient, Santa Clara, CA, USA). Global gene expression proﬁling of
liver was performed for 18 subjects studied in the methylome
analysis (6 non-obese, 6 obese non-diabetic and 6 obese type 2
diabetic) using the Human Gene ST 1.1 array (Affymetrix, Santa Clara,
CA, USA). Data was pre-processed using Plier (in Expressionis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Console). The Robust Multi-array Average (RMA) normalization
method was used to normalize all data sets. The Bioconductor Limma
package [39] was used to deﬁne differentially expressed genes
(FDR < 0.25). The Ingenuity Pathway Analysis (IPA, Ingenuity Sys-
tems, Inc., Redwood City, CA, USA) tool was used to perform pathway
analysis. Expression of selected target genes was validated in 8 non-
obese, 12 obese non-diabetic and 8 obese type 2 diabetic subjects
(reduced sample size due to RNA degradation in some samples) by
TaqMan (Life Technologies, Carlsbad, CA, USA) qPCR and normalized
to the geometric mean of RPL32 and TBP expression. cDNA synthesis
was performed with the Superscript Vilo cDNA Synthesis Kit (Invi-
trogen, Carlsbad, CA, USA).
4.4. The Integrated System for Motif Activity Response Analysis
(ISMARA)
ISMARA was performed using the genome-wide mRNA expression
data measured by Affymetrix array (see above) using methods
for automated processing and modeling of the data as described
earlier [3].
4.5. Pyrosequencing
Genomic DNA from all subjects (11 non-obese, 13 obese non-diabetic
and 11 obese type 2 diabetic) was treated with sodium bisulﬁte using
the EpiTect bisulﬁte conversion kit (Qiagen, Hilden, Germany). PCR and
sequencing primers (Table S9) were designed using the PyroMark
Assay Design software (Qiagen, Hilden, Germany). PCR was performed
using the PyroMark PCR Kit (Qiagen, Hilden, Germany). PCR products
were consequently analyzed using the PyroMark Q24 Advanced ma-
chine (Qiagen, Hilden, Germany).
4.6. Luciferase assay
The CpG-free plasmid containing a universal promoter and the Lucia
gene was obtained from InvivoGen (Cat. Code pCpGfree-promoter-
Lucia). PCR products that covered the common AFT-motif sequence
that was pyrosequenced as described above were generated by PCR
ampliﬁcation using human genomic DNA and PCR primers indicated in
Table S11. Empty pCpGfree-promoter-Lucia and PCR products were
double-digested with NsiI and BamHI (New England Biolabs, Ipswich,
MA, USA) and gel puriﬁed. Digested PCR fragments were inserted into
the digested empty plasmid using the quick ligation kit (New England
Biolabs, Ipswich, MA, USA). PIR1 competent E. coli (Life Technologies,
Carlsbad, CA, USA) were transformed with ligated DNA to amplify the
constructs. After puriﬁcation, plasmids with inserts (as validated by
Sanger-sequencing), as well as the empty plasmid were methylated
with Sss1 and SAM (New England Biolabs, Ipswich, MA, USA) for 6 h or
mock-methylated (addition of SAM without SssI). HEK293 cells were
subsequently transfected with methylated or mock-methylated
plasmid DNA using lipofectamine2000 (Life Technologies, Carlsbad,
CA, USA). Luminescence was measured 24 h after transfection in 6
replicates per gene and condition.
4.7. Western Blot analysis
Liver tissues (25 mg) were homogenized in cold lysis buffer to extract
total proteins [20 mM Tris$HCl, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Triton X-100, 1 mM b-glycerolphosphate, 2.5 mM sodium
pyrophosphate, 1 mM NaF, and 1 mM Na3VO4, pH 7.4, with protease
inhibitors (Roche Diagnostics, Mannheim, Germany)]. Homogenates
were subjected to 1 h of rotation at 4 C and centrifugation at 12,000gMOLECULAR METABOLISM 5 (2016) 171e183  2016 The Authors. Published by Elsevier GmbH. This is an
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Pierce BCA Protein assay kit (Thermo Scientiﬁc, Waltham, MA). Total
proteins (30e40 mg) were separated by SDS-PAGE on 4e10% Trise
HCl separation gels and transferred to Immobilon-P polyvinylidene
diﬂuoride membranes (Millipore, Billerica, MA, USA). Immunoblot
analysis was performed using the following antibodies: Acetyl-CoA
Carboxylase (Cell Signaling, Cat.No #3662), FASN (Sigma, Cat.No
#F9554), PRKCε (BD transduction laboratories, Cat.No #610086) and
GAPDH (FL-335) (Santa Cruz, CatNo. #sc-25778). Blots were quanti-
ﬁed using Quantity One software (BioRad, Hercules, CA, USA). Due to
unsatisfactory protein quality of some samples protein abundance from
only 9 non-obese, 7 obese non-diabetic and 5 obese type 2 diabetic
T2D-subjects could be quantiﬁed (bar graphs).
4.8. Hepatic glycogen content
Hepatic glycogen content was measured in liver tissue from all sub-
jects (n ¼ 35). Liver tissue (10 mg) was homogenized in PBS and
glycogen was determined using a glycogen assay kit (Abcam, Cam-
bridge, UK).
4.9. Hepatic triglyceride content
Liver tissue (w10 mg) was homogenized in PBS. Total triglycerides
were quantiﬁed using the Hitachi Triglyceride/Glycerol kit from Roche
(Cat. No 12146029216).
4.10. ATF6 silencing
Huh7 cell were cultured in high glucose DMEM (31966, Life Tech-
nologies) and transfected with ATF6 or scrambled control silencer
select siRNAs (s223544 and 4390843, respectively, Life Technologies)
utilizing the RNAiMAX tranfection reagent. Following transfection
(48 h), cells were treated for 6 h with tunicamycin (10 mM) (Sigma
Aldrich, St. Louis, MO, USA) or DMSO control. Cells were lysed in Trizol
followed by high capacity cDNA synthesis and Taqman qPCR
expression analysis.
4.11. Statistics
Gene expression, protein content and pyrosequencing results are
presented as mean  SEM. Clinical parameters are presented as
mean (minimumemaximum) SD. These data were tested for normal
distribution using the Skewness and Kurtosis test in SPSS Statistics
Software 21.0. When a normal distribution was observed, the statis-
tical difference between non-obese controls, obese non-diabetic pa-
tients and obese type 2 diabetic patients was determined by one-way
ANOVA with Tukey’s multiple comparisons test. Statistical analysis of
the genome-wide data from the gene array and Inﬁnium 450K
methylation array is described above.
4.12. Genome-wide data deposition
The data are deposited in the Gene Expression Omnibus (GEO) data-
base with the accession number GSE65058.
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